Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?
- 1 July 2012
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 12 (7), 561-570
- https://doi.org/10.1016/s1473-3099(12)70029-4
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- Impact of rotavirus vaccination on childhood deaths from diarrhea in BrazilInternational Journal of Infectious Diseases, 2011
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Effectiveness of Monovalent Rotavirus Vaccine (Rotarix) against Severe Diarrhea Caused by Serotypically Unrelated G2P[4] Strains in BrazilThe Journal of Infectious Diseases, 2010
- Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in MexicoThe New England Journal of Medicine, 2010
- Oral Rotavirus Vaccines: How Well Will They Work Where They Are Needed Most?The Journal of Infectious Diseases, 2009
- Rotavirus and the Indigenous Children of the Australian Outback: Monovalent Vaccine Effective in a High‐Burden SettingClinical Infectious Diseases, 2009
- Association Between Pentavalent Rotavirus Vaccine and Severe Rotavirus Diarrhea Among Children in NicaraguaJama-Journal Of The American Medical Association, 2009
- Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III studyThe Lancet, 2008